High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia

Blood

Volumn 111, Issue 1, 2008, Pages 328-337

  Herling, Marco ^a,b   Patel, Kaushali A ^a   Teitell, Michael A ^c   Konopleva, Marina ^a   Ravandi, Farhad ^a   Kobayashi, Ryuji ^a   Jones, Dan ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Hematopathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CELL GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; T CELL LEUKEMIA; TUMOR GROWTH;

EID: 38049162278     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-101519     Document Type: Article

References (49)

1. Isobe M, Russo G, Haluska FG, Croce CM. Cloning of the gene encoding the delta subunit of the human T-cell receptor reveals its physical organization within the alpha-subunit locus and its involvement in chromosome translocations in T-cell malignancy. Proc Natl Acad Sci U S A. 1988;85:3933-3937.
2. Russo G, Isobe M, Gatti R, et al. Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient. Proc Natl Acad Sci U S A. 1989;86:602-606.
3. Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet. 1991;55:1-9.
4. Hoyer KK, Herling M, Bagrintseva K, et al. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol. 2005;175:864-873.
5. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003;101:5007-5009.
6. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104:328-335.
7. Soulier J, Pierron G, Vecchione D, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31:248-254.
8. Ravandi F, O'Brien S, Jones D, et al. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005;6:234-239.
9. Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998;103:110-116.
10. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78:3269-3274.
11. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205-213.
12. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721-1726.
13. Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia: Groupe Francais d'Hematologie Cellulaire. Br J Haematol. 1998;103:488-494.
14. Brito-Babapulle V, Maljaie SH, Matutes E, Hedges M, Yuille M, Catovsky D. Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: a cytogenetic analysis with in situ hybridization. Br J Haematol. 1997;96:724-732.
15. Catovsky D, Matutes E, Brito-Babapulle V. Is T-cell CLL a disease entity [letter]? Br J Haematol. 1996;94:580.
16. Domingo-Domenech E, Gonzalez-Barca E, Salar A, Claros AD, Granena A. Indolent course as presentation in t-prolymphocytic leukaemia [letter]. Br J Haematol. 1999;105:840.
17. Hoyer JD, Ross CW, Li CY, et al. True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood. 1995;86:1163-1169.
18. Madani A, Choukroun V, Soulier J, et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood. 1996;87:1923-1927.
19. Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene. 1993;8:2475-2483.
20. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6:395-407.
21. Kunstle G, Laine J, Pierron G, et al. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol. 2002;22:1513-1525.
22. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97:3028-3033.
23. Auguin D, Barthe P, Royer C, et al. Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins. J Biol Chem. 2004;279:35890-35902.
24. French SW, Shen RR, Koh PJ, Malone CS, Mallick P, Teitell MA. A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane. Biochemistry. 2002;41:6376-6382.
25. Jaffe ES, Harris N, Stein H, Vardiman JW. Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
26. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885-892.
27. Washington LT, Huh YO, Powers LC, Duvic M, Jones D. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol. 2002;2:5.
28. Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006;20:280-285.
29. National Center for Biotechnology Information. RefSeq. http://www.ncbi.nlm.nih.gov/RefSeq/.
30. Herling M, Patel KA, Hsi ED, et al. TCL1 in B-cell tumors retains its normal B-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol. 2007;31:1123-1129.
31. Said JW, Hoyer KK, French SW, et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest. 2001;81:555-564.
32. Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood. 2002;100:3369-3373.
33. Fu ZQ, Du Bois GC, Song SP, et al. Crystal structure of MTCP-1: implications for role of TCL-1 and MTCP-1 in T cell malignancies. Proc Natl Acad Sci U S A. 1998;95:3413-3418.
34. Gritti C, Dastot H, Soulier J, et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood. 1998;92:368-373.
35. Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci U S A. 2002;99:14392-14397.
36. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269:5241-5248.
37. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther. 2005;4:977-986.
38. Laine J, Kunstle G, Obata T, Noguchi M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. J Biol Chem. 2002;277:3743-3751.
39. Ascani S, Leoni P, Fraternali Orcioni G, et al. T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? description of two cases and review of the literature. Ann Oncol. 1999;10:649-653.
40. Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just as a coactivator for Akt. Faseb J. 2007;21:2273-2284.
41. Fink SR, Paternoster SF, Smoley SA, et al. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res. 2005;29:253-262.
42. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91:12530-12534.
43. Roos J, Hennig I, Schwaller J, et al. Expression of TCL1 in hematologic disorders. Pathobiology. 2001;69:59-66.
44. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 2000;60:2095-2100.
45. Takizawa J, Suzuki R, Kuroda H, et al. Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia. Jpn J Cancer Res. 1998;89:712-718.
46. Nakayama I, Murao S, Kitazawa S, Azumi A, Yamamoto M, Maeda S. Activation of the TCL1 protein in B cell lymphomas. Pathol Int. 2000;50:191-199.
47. Teitell M, Damore MA, Sulur GG, et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci U S A. 1999;96:9809-9814.
48. Kuraishy AI, French SW, Sherman M, et al. TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. Proc Natl Acad Sci U S A. 2007;104:10175-10180.
49. Kang SM, Narducci MG, Lazzeri C, et al. Impaired T- and B-cell development in Tcl1-deficient mice. Blood. 2005;105:1288-1294.